Osteoporosis

Advanced understanding of osteoporosis requires knowledge of the molecular pathways governing bone cell differentiation and activity beyond the RANK/RANKL/OPG axis. The canonical Wnt/β-catenin signaling pathway is the master regulator of osteoblast differentiation and bone formation. Wnt ligands bind to the Frizzled receptor and its co-receptor LRP5/6 on mesenchymal stem cells, inhibiting the destruction complex (GSK-3β, axin, APC) and allowing β-catenin to accumulate in the cytoplasm and translocate to the nucleus where it activates transcription factors (TCF/LEF) that drive osteoblast commitment, proliferation, and survival. Simultaneously, Wnt signaling suppresses osteoclastogenesis by upregulating OPG expression in osteoblasts. Sclerostin, a glycoprotein encoded by the SOST gene and produced almost exclusively by osteocytes (the mechanosensory cells embedded within mineralized bone matrix), acts as a potent inhibitor of Wnt signaling by binding to LRP5/6 and preventing Wnt ligand engagement. When mechanical loading is applied to bone, osteocytes downregulate sclerostin production, releasing the brake on Wnt signaling and promoting bone formation at sites of mechanical strain. In disuse and aging, sclerostin levels rise, suppressing formation and contributing to net bone loss.

Cathepsin K is a cysteine protease expressed by activated osteoclasts within the resorption lacuna (Howship lacuna). After osteoclasts dissolve the mineral phase of bone using hydrochloric acid secreted through the ruffled border, cathepsin K degrades the exposed organic matrix, primarily type I collagen. This enzyme operates optimally at the acidic pH of the resorption lacuna and is the rate-limiting step in organic matrix degradation. Cathepsin K inhibitors (odanacatib) were developed to reduce resorption while preserving the osteoclast itself, theoretically maintaining the coupling signals that osteoclasts provide to osteoblasts, but clinical development was halted due to cerebrovascular adverse effects. Understanding these pathways informs the mechanism of newer therapeutics: romosozumab (anti-sclerostin monoclonal antibody) unleashes Wnt-mediated bone formation while simultaneously reducing resorption, producing a dual-effect anabolic agent; teriparatide (recombinant PTH 1-34) given intermittently paradoxically stimulates osteoblast activity by preferentially activating the formation arm of bone remodeling; and denosumab (anti-RANKL monoclonal antibody) mimics OPG by sequestering RANKL and profoundly suppressing osteoclast maturation and function.